21) HFV
Abstract
Hemorrhagic Fever Virus (HFV) Therapeutic Medical Countermeasures (MCM), which will provide broad spectrum (multi-agent), platform-based therapeutics against Ebola and Marburg viruses. TMT efforts to be conducted for the medical countermeasures during this period include Phase 1 human clinical safety trials, non-clinical studies to demonstrate safety and efficacy, and animal model development / refinement. DoD anticipates the FDA will require use of the Animal Rule for the HFV therapeutic medical countermeasures, which allows for the demonstration of efficacy in relevant animal model(s) when human testing is not ethically feasible.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2013
- Source ID
- fdb319f3b742b93261ba204e4e97df65